Phase 2 Trial Reports Positive Outcomes with Treatment Combination for Ovarian Cancer

Rákkutatás · Ovarian cancer

The combination of pembrolizumab, bevacizumab and oral cyclophosphamide was well tolerated and demonstrated clinical benefit and durable treatment responses in patients with recurrent ovarian cancer.

Phase 2 non‑randomized clinical trial found that pembrolizumab, bevacizumab and oral cyclophosphamide were well tolerated and demonstrated clinical benefit and durable treatment responses in patients with recurrent ovarian cancer.

This combination offers a tolerable, effective strategy that extends disease control in recurrent ovarian cancer and may overcome the limited efficacy of checkpoint inhibitors alone.

Bizonyítékszint: Korai humán adat. Kis vagy feltáró emberi adat.

Eredeti forrás

Kapcsolódó jelek